Nokia and Elisa successfully complete Europe’s first Cloud RAN trial powered by In-Line acceleration
Nokia and Elisa successfully complete Europe’s first Cloud RAN trial powered by In-Line acceleration
- Europe’s first Cloud RAN trial using In-Line acceleration realized in Elisa’s 5G network
- Successfully executed 5G data calls, with commercial 5G user equipment, confirming the feature richness and high performance of Nokia’s anyRAN approach
- Project confirms Nokia’s industry leadership in developing Cloud RAN market, which offers mobile operators more choice in building 5G networks
- First 5G data calls in Cloud RAN marks a significant milestone in Elisa's overall cloudification journey
- Supports Elisa’s ambition to pioneer bringing cloud networking benefits, such as scalability and agility, to Finnish customers with highly automated processes
13th October 2023
Espoo, Finland – Nokia and Elisa today announced that they have successfully completed the industry’s first trial of Cloud RAN powered by In-Line acceleration. The successful trial took place at Elisa’s headquarters in Finland and utilized its commercial 5G Standalone RAN and 5G Core. The trial builds on Nokia’s anyRAN approach, which was introduced to ensure the feature richness, energy efficiency, and high performance of Cloud RAN compared to purpose-built RAN. Using In-Line layer 1 (L1) acceleration ensures each of these aspects while enabling flexibility to select between x86 and ARM-based ecosystems.
The trial took place in an over-the-air environment, utilizing 100MHz cells on the n78 spectrum band (3.5 GHz band), which globally is the most common 5G capacity band. Data calls were successfully performed with a selection of both test and commercial user devices. The trial followed a Nokia reference design with a CaaS layer from RedHat as well as an x86 server architecture. The feature performance delivered by Nokia’s anyRAN approach enabled immediate interoperability with 5G user equipment and Elisa’s 5G core network.
Elisa is pursuing network cloudification which it considers a key area in sparking innovation and enhancing the scalability of network services. The first commercial deployments are expected to take place over the next few years in Finland and will continue the cloudification evolution seen in core networks. Cloudification will deliver higher levels of network automation supporting the flexibility and agility of end-user service provisioning.
Nokia’s anyRAN is an open approach to building future-ready radio access networks together with an ecosystem of industry partners, which unlocks a collaborative advantage. It’s designed to give mobile operators and enterprises more flexibility in their choice of cloud infrastructure software, hardware, and technology suppliers. With Nokia, operators have the opportunity to evolve to Hybrid RAN with both Cloud RAN and purpose-built RAN deployments co-existing to deliver a consistent, high-quality performance.
Markus Kinnunen, Vice President, Cloud Services, Elisa said: “Elisa is a pioneer in automation and in introducing the benefits of network cloudification to Finnish customers. This first call using Cloud RAN is a remarkable milestone on our cloudification journey. After already taking the first steps in cloudifying the telco network core, this transformation is now also expanding towards the access network. The key benefits of Cloud RAN include the diverse network service platforms and scalability for different kinds of customer needs. In the future, we can provide more agile network services to our customers, whose network usage is transforming closer to the network edge.”
Mark Atkinson, Head of RAN at Nokia, said: “This important trial with our long-term partner, Elisa, confirms the effectiveness and maturity of Nokia’s anyRAN approach and our open Cloud RAN architecture powered by In-Line L1 acceleration. Unlike other suppliers, we commit to feature parity between Cloud RAN and purpose-built RAN and we ensure that our customers can flexibly evolve to Cloud RAN with choices in Cloud infrastructure and data center hardware. Nokia’s approach to Cloud RAN means we will partner with communication service providers (CSPs) and enterprises to drive efficiency, innovation, openness, and scale in their RAN evolution.”
Webpage: Nokia AirScale Cloud RAN
Webpage: Nokia anyRAN
Whitepaper: Cloud RAN: A Guide to Acceleration Options
Blog: In-Line architecture: bringing efficiency and performance to Cloud RAN
Blog: The collaborative advantage: Nokia and partners delivering best-in-class Cloud RAN solutions
At Nokia, we create technology that helps the world act together.
As a B2B technology innovation leader, we are pioneering networks that sense, think and act by leveraging our work across mobile, fixed and cloud networks. In addition, we create value with intellectual property and long-term research, led by the award-winning Nokia Bell Labs.
Service providers, enterprises and partners worldwide trust Nokia to deliver secure, reliable and sustainable networks today – and work with us to create the digital services and applications of the future.
Elisa’s mission is a sustainable future through digitalisation. We are a pioneer in telecommunications and digital services, and in 5G. We provide sustainable solutions for over 2.8 million consumer, corporate and public administration customers in our core markets of Finland and Estonia, as well as in over 100 countries internationally. In Finland, Elisa is a market leader in telecommunications, and our international cooperation partners include e.g. Vodafone and Tele2. Elisa is listed on the Nasdaq Helsinki. In 2022, our revenue was EUR 2.1 billion and we employed 5,600 people in more than 20 countries. Elisa is a carbon-neutral company. elisa.comTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Managers’ transactions9.12.2023 18:12:40 CET | Press release
December 9, 2023 Announcement no. 21 Managers’ transactions COPENHAGEN, DENMARK and BOSTON, MA, December 9, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), has received notice pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transaction related to shares in BioPorto made by persons discharging managerial responsibilities in BioPorto and/or persons closely related with them. 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Singer Asefzadeh Family Holding Trust 2. Reason for the notification a) Position/status Closely associated person to Michael S. Singer, member of the Board of Directors of BioPorto A/S b) Initial notification/amendment Initial notification 3. Details of the issuer a) Name BioPorto A/S b) LEI 5299004SWFL5JAN4W830 4. Details of the transaction(s) a) Description of the financial instrument type of instrument and Identification code Shares, ISIN code DK0011048619 b) Nature o
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)9.12.2023 18:00:00 CET | Press release
Media Release COPENHAGEN, Denmark; December 9, 2023 Data from the pivotal phase 1/2 EPCORE™ NHL-1 study showed 82 percent overall response rate (ORR), 63 percent complete response (CR) and 67 percent minimal residual disease (MRD) negativity in patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with subcutaneous epcoritamab Results presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition include data from an optimized step-up dosing schedule for FL patients showing meaningful reduction in risk and severity of cytokine release syndrome (CRS) Follicular lymphoma is the second most common form of non-Hodgkin’s lymphoma, is considered incurable and can be difficult to treat in the R/R setting Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) todayannounced new data from the ongoing phase 1/2 EPCORE™ NHL-1 clinical trial investigating epcoritamab (DuoBody® CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, demo
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG51019.12.2023 18:00:00 CET | Press release
Additional safety and efficacy data further support potential of innovative, decentralized approach to CAR-T manufacturing and transformational impact on patients with severe hematologic cancersTwo poster presentations include recent data updates and additional data not included in the ASH abstracts Galapagos to host a Key Opinion Leader (KOL) event with live webcast on Sunday, 10 December 2023 at 11:00 am PT/20:00 CET Mechelen, Belgium; 9 December 2023, 18:00 CET; Galapagos NV (Euronext & NASDAQ: GLPG) topresent additional encouraging clinical data from the ongoing Phase 1/2 CD19 CAR-T studies, EUPLAGIA-1 with GLPG5201 and ATALANTA-1 with GLPG5101, in patients with relapsed/refractory chronic lymphocytic leukemia (rrCLL), with or without Richter transformation, and non-Hodgkin lymphoma (rrNHL), during two poster sessions at the 65th American Society of Hematology (ASH) Annual Meeting taking place in San Diego, from 9-12 December. “We are very pleased to share promising new data from o
New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A9.12.2023 17:30:00 CET | Press release
Phase III HAVEN 7 primary data presented at ASH 2023 provide additional confidence in the favourable efficacy and safety profile of subcutaneous Hemlibra given soon after birth 1At nearly two years median follow-up in the descriptive, single-arm study, no babies experienced spontaneous bleeds requiring treatment, and all treated bleeds were as a result of trauma 1Safety results were consistent with previous studies of Hemlibra, with no new safety signals observed 1The HAVEN 7 study was developed in collaboration with the haemophilia A community, to generate additional evidence for the prophylactic treatment of infants with haemophilia A Basel, 09 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the primary analysis of the Phase III HAVEN 7 study reinforced the efficacy and safety of Hemlibra® (emicizumab) in previously untreated or minimally treated infants with severe haemophilia A without factor VIII inhibitors. Results showed that Hemlibra achieved meaningful
Bulletin from Annual General Meeting in SkiStar AB9.12.2023 16:00:00 CET | Press release
At SkiStar AB (publ)’s annual general meeting, held in Sälen on 9 December 2023, the following decisions were made. A dividend of SEK 2.60 per share was adopted. Record day 12 December 2023.Lena Apler, Fredrik Paulsson, Gunilla Rudebjer, Anders Sundström, Anders Svensson and Vegard Søraunet were re-elected to the board and Carina Åkerström was elected as new board member.Anders Sundström was re-elected chairman of the board.Board fees, including committee fees, were raised to a total of SEK 2,890,000 (2022: SEK 2,810,000). The fees shall be distributed as follows: SEK 670,000 (650,000) to the chairman of the board and SEK 310,000 (300,000) each to the other non-executive directors. Audit committee members will receive total fees of SEK 240,000 (unchanged), distributed as follows: SEK 120,000 to the committee chairman and SEK 60,000 to each of the other two members. Remuneration committee members will receive total fees of SEK 120,000 (unchanged), distributed as follows: SEK 60,000 to t